

Congenital Hyperinsulinism Market Analysis 2034: Epidemiology Insights, Pipeline, Recent Drug Approvals by DelveInsight

DelveInsight's Congenital Hyperinsulinism Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

NEVADA, LAS VEGAS, UNITED STATES, June 18, 2024 /EINPresswire.com/ --

DelveInsight's "Congenital Hyperinsulinism Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Congenital Hyperinsulinism, historical and

forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Congenital Hyperinsulinism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Congenital Hyperinsulinism Market Forecast](#)

Some of the key facts of the Congenital Hyperinsulinism Market Report:

The Congenital Hyperinsulinism market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

Key Congenital Hyperinsulinism Companies: Zealand Pharma, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger BioPharma-ceuticals, Crinetics, AmideBio, Xeris Pharmaceuticals, Hanmi Pharmaceutical, and others

Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

DelveInsight has analyzed mutation-specific data of Congenital Hyperinsulinism, which suggests that mutations in the ABCC8 and KCNJ11 genes are the most common causes of Congenital Hyperinsulinism while mutations in several other genes (GLUD1, GCK, HADH, SLC16A1, HNF4A, and HNF1A) are also involved in the development of Congenital Hyperinsulinism . In the United States, in 2021, mutations in ABCC8 and KCNJ11 genes accounted for 4,917 cases, while other gene mutations accounted for 4,023 cases.

PROGLYCEM (diazoxide) is the only therapy for CHI, approved by the FDA and the EMA. Various new therapies are currently in development. Some of the most prominent ones include dasiglucagon (Zealand Pharma), and RZ358 (Rezolute), among others.

According to DelveInsight's estimates, RZ358 is expected to garner the highest market share by 2034, in the seven major markets.

Zealand Pharma intends to resubmit its NDA to the FDA in the first half of 2024 for ZEGALOGUE (dasiglucagon), investigated to treat pediatric hypoglycemia in CHI patients, following a 2023 Complete Response Letter related to manufacturing facility issues.

As per DelveInsight's estimates, the EU4 and the UK exhibited the highest diagnosed prevalent cases of CHI compared to the US and Japan. Together, they represented around 70% of the total cases of CHI among the 7MM in 2023

In the EU5 countries, the diagnosed prevalence of Congenital Hyperinsulinism was maximum in the United Kingdom with 2,398 cases, followed by Germany with 2,066 cases in 2021. While, the least number of cases were in Spain, with 1,286 cases in 2021 respectively.

In Japan, the diagnosed prevalence of Congenital Hyperinsulinism was 2,685 in 2021 growing at a CAGR of 1.0%.

The Congenital Hyperinsulinism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Hyperinsulinism pipeline products will significantly revolutionize the Congenital Hyperinsulinism market dynamics.

Congenital Hyperinsulinism Overview

Congenital Hyperinsulinism is a rare genetic disorder marked by excessive insulin production, leading to dangerously low blood sugar levels in infants and children. It stems from mutations in genes that regulate insulin secretion in the pancreas. Symptoms can include seizures, lethargy, poor feeding, and developmental delays. Early diagnosis is critical to prevent potential long-term complications such as brain damage. Treatment options include medications to stabilize blood sugar, frequent feedings, and in severe cases, partial removal of the pancreas through surgery. Long-term monitoring is essential for proper growth and development. Providing supportive care and educational resources is crucial for families affected by this condition.

Congenital Hyperinsulinism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congenital Hyperinsulinism Epidemiology Segmentation:

The Congenital Hyperinsulinism market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Congenital Hyperinsulinism

Prevalent Cases of Congenital Hyperinsulinism by severity

Gender-specific Prevalence of Congenital Hyperinsulinism Diagnosed Cases of Episodic and Chronic Congenital Hyperinsulinism

Download the report to understand which factors are driving Congenital Hyperinsulinism epidemiology trends @ [Congenital Hyperinsulinism Epidemiology Forecast](#)

Congenital Hyperinsulinism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Hyperinsulinism market or expected to get launched during the study period. The analysis covers Congenital Hyperinsulinism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Hyperinsulinism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Hyperinsulinism Therapies

Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136

Congenital Hyperinsulinism Key Companies

Zealand Pharma, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger BioPharmaceuticals, Crinetics, AmideBio, Xeris Pharmaceuticals, Hanmi Pharmaceutical

Congenital Hyperinsulinism Market Outlook

There is only one approved therapy for CHI in the market, namely, PROGLYCEM (diazoxide) – a non-diuretic benzothiadiazole derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals. A number of children with CHI are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide/lanreotide are required in such children. Somatostatin receptor analogs (SSRAs), typically octreotide/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long-acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long-acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that severity of CHI may naturally reduce over time, the use of fixed-dose long-acting SSRAs may be

considered disproportionate.

Scope of the Congenital Hyperinsulinism Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Congenital Hyperinsulinism Companies: Zealand Pharma, Eli Lilly, Novo Nordisk, Novartis, Rezolute, Eiger BioPharma-ceuticals, Crinetics, AmideBio, Xeris Pharmaceuticals, Hanmi Pharmaceutical, and others

Key Congenital Hyperinsulinism Therapies: Dasiglucagon, RZ358, Avexitide, CRN04777, ABG-023, HM15136, and others

Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies

Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Congenital Hyperinsulinism Unmet Needs, KOL's views, Analyst's views, Congenital Hyperinsulinism Market Access and Reimbursement

To know more about Congenital Hyperinsulinism companies working in the treatment market, visit @ [Congenital Hyperinsulinism Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Congenital Hyperinsulinism Market Report Introduction
2. Executive Summary for Congenital Hyperinsulinism
3. SWOT analysis of Congenital Hyperinsulinism
4. Congenital Hyperinsulinism Patient Share (%) Overview at a Glance
5. Congenital Hyperinsulinism Market Overview at a Glance
6. Congenital Hyperinsulinism Disease Background and Overview
7. Congenital Hyperinsulinism Epidemiology and Patient Population
8. Country-Specific Patient Population of Congenital Hyperinsulinism
9. Congenital Hyperinsulinism Current Treatment and Medical Practices
10. Congenital Hyperinsulinism Unmet Needs
11. Congenital Hyperinsulinism Emerging Therapies
12. Congenital Hyperinsulinism Market Outlook
13. Country-Wise Congenital Hyperinsulinism Market Analysis (2020–2034)
14. Congenital Hyperinsulinism Market Access and Reimbursement of Therapies
15. Congenital Hyperinsulinism Market Drivers
16. Congenital Hyperinsulinism Market Barriers
17. Congenital Hyperinsulinism Appendix
18. Congenital Hyperinsulinism Report Methodology
19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/720986807>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.